# Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT00003560** · PHASE2 · UNKNOWN · sponsor: **Herbert Irving Comprehensive Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Endometrial Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00003560
- **Lead sponsor:** Herbert Irving Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003560, "Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00003560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*